Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
RESEARCH TOOLSreports
ZNTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.61 - $18.07
Previous CloseN/A
Volume750.15K
Average Volume (3M)2.60M
Market Cap
$176.74M
Enterprise Value-$86.30M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Feb 26, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding71,265,400
10 Day Avg. Volume1,798,718
30 Day Avg. Volume2,601,538
Standard Deviation0.22
R-Squared0.15
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.36
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit62.13
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$5.97Price Target Upside135.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
---
Zentalis Pharmaceuticals News
PremiumCompany Announcements
Zentalis Pharmaceuticals Announces New Study for Azenosertib
PremiumCompany Announcements
Zentalis Pharmaceuticals Restructures to Advance Oncology Product---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe focus on azenosertib monotherapy in CCNE1+ platinum-resistant ovarian cancer patients shows an objective response rate of over 30%, which is encouraging compared to the 4-13% response rate for standard chemotherapy.
Regulatory PathwayWith a clear regulatory pathway, a biomarker-driven strategy, and a significant market opportunity, Zentalis is well-positioned to deliver a transformative therapy for PROC patients.
Safety ProfileZNTL's safety profile for its treatment appears generally superior to standard chemotherapy, which is a reassuring factor for investors.
Bears Say
Dose OptimizationThe FDA is requesting further dose optimization for the 400mg regimen, indicating that the current dose may not be optimal yet.
FDA Dose Evaluation ConcernsThe FDA wants more dose evaluation, thus there is still no confirmed go forward dose with azeno, which was a negative surprise for investors.
Price Target ReductionThe company's price target has been reduced from $7.00 to $5.00, reflecting adjustments in the company's latest pipeline and strategy.
---
Ownership Overview
5.16% Insiders
28.15% Mutual Funds
45.97% Other Institutional Investors
12.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $1.61 and its highest was $18.07 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Zentalis Pharmaceuticals’s market cap is $176.74M.
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Zentalis Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.91 by $0.35.
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -0.69.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 71,265,400 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Zentalis Pharmaceuticals reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.91. Following the earnings report the stock price went up 1.587%.
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Currently, no hedge funds are holding shares in ZNTL
---
Zentalis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.97 (135.97% Upside)
$5.97 (135.97% Upside)
Blogger Sentiment
Bullish
ZNTL Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $157.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.49%
12-Months-Change
Fundamentals
Return on Equity
-42.89%
Trailing 12-Months
Asset Growth
-23.06%
Trailing 12-Months
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.
---
ZNTL Stock 12 Month Forecast
Average Price Target
$5.97
▲(135.97% Upside)
Technical Analysis
Best Analysts Covering ZNTL
1 Year
1 Year Success Rate
1/15 ratings generated profit
1 Year Average Return
-49.63%
reiterated a buy rating 23 days ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 6.67% of your transactions generating a profit, with an average return of -49.63% per trade.
---